Vincristine in steroid-resistant nephrotic syndrome.
The therapeutic response to vincristine was examined in seven children (aged 2-15 years) with corticosteroid-resistant (CR) nephrotic syndrome (NS) with focal and segmental glomerulosclerosis (FGS). Five were also resistant to cyclophosphamide. Vincristine was given weekly (1.5 mg/m2 intravenously) for 8 weeks. Simultaneously, prednisone (60 mg/m2 per day, orally) was given for 4 weeks and then gradually tapered. Two of these patients had a complete and stable remission; in five no benefit was observed. It was not possible to identify any characteristics to predict the response to vincristine. Although there is a case for trying vincristine therapy in CR NS with FGS, the results of this study are not encouraging and a better understanding of its action and indications is necessary.
Almeida
M P
MP
Department of Paediatrics, University of Lisbon, Portugal.
Almeida
H A
HA
Rosa
F C
FC
D000284:Administration, Oral; D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000627:therapeutic use; D004351:Drug Resistance; D005260:Female; D005919:Glomerular Filtration Rate; D005923:Glomerulosclerosis, Focal Segmental / Q000150:complications; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D009404:Nephrotic Syndrome / Q000150:complications / Q000188:drug therapy*; D011241:Prednisone / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage / Q000627:therapeutic use*
D014750:Vincristine; D003520:Cyclophosphamide; D011241:Prednisone